Respiratory Infections News

Researchers linked more than 1 million deaths in Africa in 2019 to antimicrobial resistance, more than half of which were linked to just four pathogens.

A second tuberculosis outbreak linked to a viable bone allograft product contaminated with Mycobacterium tuberculosis resulted in five more cases and two deaths, according to the outbreak investigation.

Maternal influenza vaccination during pregnancy was associated with reduced chances of influenza-associated ED visits or hospitalizations in infants aged younger than 6 months, according to a study published in JAMA Pediatrics.

Multiple prevention tools against respiratory syncytial virus in children became available in the United States this year.

The monoclonal antibody nirsevimab prevented hospitalizations for respiratory syncytial virus-associated disease among infants “in conditions that approximated real-world settings,” researchers wrote in The New England Journal of Medicine.

COVAX, the multinational program launched in 2020 to deliver COVID-19 vaccines to low- and lower-middle income countries, will end on Dec. 31, 2023, as the vaccines shift to routine immunization programs.

New guidance was published in 2023 for STD prevention, diabetic foot infections, infective endocarditis and more.

SARS-CoV-2 rebound risk is more likely related to the individual person, rather than reinfection or resistance to treatment such as Paxlovid, according to two studies.

Efforts to raise flagging childhood vaccination rates increased in 2023 as new shots hit the market.

The FDA in 2023 approved treatments for several hospital-associated infections and fully approved a long-used COVID-19 medication, among other non-vaccine-related regulatory decisions.